NO20060518L - Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler - Google Patents

Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler

Info

Publication number
NO20060518L
NO20060518L NO20060518A NO20060518A NO20060518L NO 20060518 L NO20060518 L NO 20060518L NO 20060518 A NO20060518 A NO 20060518A NO 20060518 A NO20060518 A NO 20060518A NO 20060518 L NO20060518 L NO 20060518L
Authority
NO
Norway
Prior art keywords
ion channels
modulators
voltage controlled
controlled ion
pyrimidines useful
Prior art date
Application number
NO20060518A
Other languages
English (en)
Norwegian (no)
Inventor
Jesus E Gonzales Iii
Dean Mitchell Wilson
Esther Martinborough
Nicole Zimmermann
Timothy Donald Neuberg
Andreas Peter Termin
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20060518L publication Critical patent/NO20060518L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20060518A 2003-07-02 2006-02-01 Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler NO20060518L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48436203P 2003-07-02 2003-07-02
US50020003P 2003-09-04 2003-09-04
PCT/US2004/021440 WO2005003099A2 (fr) 2003-07-02 2004-07-02 Pyrimidines utilisees comme modulateurs des canaux ioniques sensibles au voltage

Publications (1)

Publication Number Publication Date
NO20060518L true NO20060518L (no) 2006-03-07

Family

ID=33567720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060518A NO20060518L (no) 2003-07-02 2006-02-01 Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler

Country Status (14)

Country Link
US (2) US7816529B2 (fr)
EP (1) EP1638955A2 (fr)
JP (1) JP2007521287A (fr)
KR (1) KR20060032190A (fr)
AR (1) AR045010A1 (fr)
AU (1) AU2004253962A1 (fr)
CA (1) CA2531061A1 (fr)
IL (1) IL172937A0 (fr)
MX (1) MXPA06000051A (fr)
NO (1) NO20060518L (fr)
PE (1) PE20051029A1 (fr)
RU (1) RU2006102955A (fr)
TW (1) TW200519094A (fr)
WO (1) WO2005003099A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006102955A (ru) * 2003-07-02 2007-08-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
WO2006100212A1 (fr) * 2005-03-22 2006-09-28 Neurosearch A/S Pyrazolyl-pyrimidines comme agents de modulation de la voie du potassium et leur utilisation medicale
WO2006119451A1 (fr) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines et pyrazines utilisees comme modulateurs des canaux ioniques
EP1877381A1 (fr) * 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyridines utiles en tant que modulateurs de canaux ioniques
WO2006130493A2 (fr) * 2005-05-31 2006-12-07 Vertex Pharmaceuticals Incorporated Heterocycles utiles comme modulateurs de canaux ioniques
WO2007125331A2 (fr) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-éthyl-amino-aryles (aeaa) et leurs applications
JP2009539988A (ja) * 2006-06-12 2009-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルの調節因子として有用なチエノピリミジン
EP2132196A1 (fr) 2007-02-26 2009-12-16 Pfizer Products Inc. Composés hétérocycliques utiles dans le traitement de maladies et de conditions
US20080221103A1 (en) * 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
AU2008256905B2 (en) 2007-05-22 2014-05-08 Wyeth Improved processes for making hydrazides
JP2009007273A (ja) * 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
KR101546111B1 (ko) * 2007-10-11 2015-08-20 글락소스미스클라인 엘엘씨 신규한 ｓＥＨ 억제제 및 그의 용도
DE102007061756A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
US20100311775A1 (en) * 2008-01-30 2010-12-09 Smithkline Beecham Corporation Novel sEH Inhibitors and Their Use
EP2240026A4 (fr) * 2008-01-30 2011-10-19 Glaxosmithkline Llc NOUVEAUX INHIBITEURS DE sEH ET LEUR UTILISATION
EP2240021A4 (fr) * 2008-01-30 2011-08-17 Glaxosmithkline Llc Nouveaux inhibiteurs de seh et leur utilisation
US20090198057A1 (en) * 2008-02-05 2009-08-06 Pu-Ping Lu Certain Chemical Entities, Compositions, and Methods
KR101406433B1 (ko) 2008-09-22 2014-06-13 카이맨 케미칼 컴파니 인코포레이티드 Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도
AR075196A1 (es) * 2009-02-03 2011-03-16 Otsuka Pharma Co Ltd Un derivado de cianopirimidina para el tratamiento de una enfermedad ocular
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
CN103221408A (zh) * 2010-09-13 2013-07-24 诺瓦提斯公司 三嗪-*二唑类化合物
US9199962B2 (en) * 2011-07-07 2015-12-01 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
TW201706265A (zh) 2015-03-09 2017-02-16 必治妥美雅史谷比公司 做為Ｒｈｏ激酶（ＲＯＣＫ）抑制劑之內醯胺
GB201721751D0 (en) * 2017-12-22 2018-02-07 Adorx Therapeutics Ltd Compounds
WO2022217118A1 (fr) * 2021-04-09 2022-10-13 Quanta Therapeutics, Inc. Modulateurs de ras à base de pyrimidine et leurs utilisations
TW202339734A (zh) * 2021-12-23 2023-10-16 比利時魯汶大學 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之２－吡唑苯胺及相關類似物
WO2023154766A1 (fr) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Modulateurs de kras et leurs utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB901749A (en) * 1957-12-06 1962-07-25 Ciba Ltd New 2-substituted pyrimidines
US3040047A (en) * 1960-04-04 1962-06-19 Takeda Pharmaceutical 2-(pyrazol-1-yl)-pyrimidine derivatives
US3850928A (en) * 1969-11-04 1974-11-26 American Home Prod Substituted 6-alkylamino-2-phenyl-5-pyrimidine carboxylic acids
US3850931A (en) * 1971-06-25 1974-11-26 American Home Prod 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters
US3759922A (en) * 1971-06-25 1973-09-18 American Home Prod Preparation of pyrimido(5,4-c)(1,5) benz oxazepin-5(11h)-ones and intermediates
US3860596A (en) * 1972-08-31 1975-01-14 American Home Prod 2-aryl-4-substituted-amino-5-pyrimidyl derivatives
DE2341925A1 (de) * 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
FR2263750A1 (en) 1974-03-12 1975-10-10 Delalande Sa N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc.
FR2281117A2 (fr) 1974-08-09 1976-03-05 Ugine Kuhlmann Nouvelles piperazino-pyrimidines utilisables comme medicaments
JPS6044303B2 (ja) 1975-02-25 1985-10-02 大日本製薬株式会社 ２−環状アミノ−４−アミノピリミジン誘導体の製造法
WO1987004928A1 (fr) * 1986-02-24 1987-08-27 Mitsui Petrochemical Industries, Ltd. Agents therapeutiques de la neuropathie
JP2005508833A (ja) * 2001-02-20 2005-04-07 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャネル・モジュレーターとしての２，４−ジ置換ピリミジン−５−カルボキサミド誘導体
WO2003097615A1 (fr) * 2002-05-17 2003-11-27 Scios, Inc. Traitement de troubles de fibro-proliferation au moyen d'inhibiteur de tgf-$g(b)
RU2006102955A (ru) * 2003-07-02 2007-08-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов
WO2006119451A1 (fr) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines et pyrazines utilisees comme modulateurs des canaux ioniques

Also Published As

Publication number Publication date
EP1638955A2 (fr) 2006-03-29
US7816529B2 (en) 2010-10-19
AR045010A1 (es) 2005-10-12
US8324220B2 (en) 2012-12-04
TW200519094A (en) 2005-06-16
AU2004253962A1 (en) 2005-01-13
CA2531061A1 (fr) 2005-01-13
KR20060032190A (ko) 2006-04-14
WO2005003099A2 (fr) 2005-01-13
MXPA06000051A (es) 2006-03-21
IL172937A0 (en) 2006-06-11
RU2006102955A (ru) 2007-08-20
US20050049247A1 (en) 2005-03-03
WO2005003099A3 (fr) 2005-05-12
JP2007521287A (ja) 2007-08-02
US20110003814A1 (en) 2011-01-06
PE20051029A1 (es) 2005-12-07

Similar Documents

Publication Publication Date Title
NO20060518L (no) Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20061080L (no) Kondenserte pyramidinforbindelser som inhibitorer av spenningsstyrte ionekanaler
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
MX2010003009A (es) Piridil sulfonamidas como moduladores de canales ionicos.
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
NO20082746L (no) Kinazoliner anvendelige som modulatorer for spenningsstyrte ionekanaler
WO2006050476A3 (fr) Modulateurs de canaux ioniques et leurs methodes d'utilisation
AU2008321142A8 (en) Heterocyclic derivatives as modulators of ion channels
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application